Navigation Links
Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
Date:3/17/2008

NASDAQ: CRME TSX: COM

VANCOUVER, March 17 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) today announced positive interim clinical results from its 90-day Phase 2b study of vernakalant (oral). The interim analysis demonstrated statistically significant efficacy for the patient group receiving 500mg b.i.d. of vernakalant (oral) as compared to placebo. The safety data from the interim analysis also suggests that vernakalant (oral) was well-tolerated in the atrial fibrillation population studied during the dosing period under analysis.

A Kaplan-Meier analysis of the 446 patients included in the interim dataset demonstrated a significant efficacy benefit for the 500mg dosing group as compared to placebo (two-sided, p<0.05). Median time to recurrence of atrial fibrillation was greater than 90 days for the 500mg dosing group, compared to 39 days for the placebo group. 52% of patients in the 500mg dosing group (n=110) completed the study in normal heart rhythm compared to 39% of patients receiving placebo (n=118). The interim efficacy analysis for the 150mg (n=110) and 300mg (n=108) dosing groups had not achieved statistical significance at the interim timepoint.

"This larger-scale, longer-term study of vernakalant (oral) was designed to find the appropriate dose to take into Phase 3, and to confirm our assumptions regarding safety," said Dr. Charles Fisher, Executive Vice President and Chief Medical Officer of Cardiome. "While the study is ongoing and we must await the final data before drawing conclusions, these statistically significant and clinically significant efficacy results as well as the attractive safety profile observed in this interim analysis strongly support our belief in the exciting potential of vernakalant (oral) as a therapy for atrial fibrillation."

The safety data for all dosing groups suggests that vernakalant (oral) was well-tolerated within the interim safety populatio
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. Cardiome to Hold Investor Update Call
3. Cardiome Updates Guidance
4. Cardiome Initiates Phase 1 Study for GED-aPC
5. Cardiome To Release Third Quarter Results
6. Cardiome to Present at CIBC Conference
7. Cardiome to Present at ThinkEquity Conference
8. Cardiome to Present at Bear Stearns Conference
9. Weight Watchers Announces Election of Kim Roy to Board of Directors
10. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
11. Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- In people with sex ... similar to that seen in drug addicts as they ... clear differences in brain activity between patients who have ... those of drug addicts," study author Dr. Valerie Voon, ... a university news release. Voon,s research involved 19 ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
(Date:7/11/2014)... Ohio (PRWEB) July 11, 2014 As ... 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number of ... blood sugar, abdominal issues and even death from the ... , According to the Times report , a ... in 2013 reported by patients was almost 14% of ...
(Date:7/11/2014)... News) -- Delaying surgery to repair damage to the anterior ... of the knee -- could increase a young athlete,s risk ... records of 130 patients, aged 8 to 16, who had ... than six weeks after their injury, 37 had surgery six ... than three months after their injury. The youngsters who ...
(Date:7/11/2014)... 2014 Riverside Health System became the first ... Virginia in late 2012 and now, in partnership with Williamsburg ... throughout the Williamsburg and Newport News region. , Also known ... benefits to independent older adults who wish to remain in ... net of continuing care services as well as control over ...
Breaking Medicine News(10 mins):Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... In a society that hails monogamy as,the tried and ... that there is a large group of people who ... relationship at a time. Others,are aware of and curious ... to turn to find information or how to look ...
... Net sales $50.8 million, up 25% versus year ago on operating ... historic high commodity costs - Net loss $1.2 million, ... Targeted 30% growth in net sales on operating basis (1), ... today announced its results for the first quarter ended,March 31, 2008. ...
... HIV/AIDS,Policy announced today that the Web site AIDS.gov, a ... now has an innovative look,and feel that incorporates a ... blog ( http://blog.aids.gov ), one of AIDS.gov,s latest features,focuses ... based on,the Internet - in the fight against HIV/AIDS. ...
... condition associated with loss of blood supply to the ... for a type of depression in the elderly related to ... and researchers have discovered why some patients with this condition ... findings were to be presented Wednesday during a news conference ...
... May 7, 2008 ---Alzheimers disease (AD) is an incurable ... even more rapidly as the Baby Boom generation enters ... are only partially effective in some patients. New strategies ... in todays Journal of Neuroscience, researchers in the laboratory ...
... ... - EPS of $0.38, up 36% from first quarter 2007, - Record new business awards of $180 million, up 20% ... 2007, - Total business authorizations of $917 million, ... 2007, CINCINNATI, May 7 ...
Cached Medicine News:Health News:'The Polyamory Handbook': New Guide Covers Entire Spectrum of Rapidly Growing Relationship Style 2Health News:Smart Balance Announces 2008 First-Quarter Results 2Health News:Smart Balance Announces 2008 First-Quarter Results 3Health News:Smart Balance Announces 2008 First-Quarter Results 4Health News:Smart Balance Announces 2008 First-Quarter Results 5Health News:Smart Balance Announces 2008 First-Quarter Results 6Health News:Smart Balance Announces 2008 First-Quarter Results 7Health News:Smart Balance Announces 2008 First-Quarter Results 8Health News:Smart Balance Announces 2008 First-Quarter Results 9Health News:Smart Balance Announces 2008 First-Quarter Results 10Health News:Smart Balance Announces 2008 First-Quarter Results 11Health News:Smart Balance Announces 2008 First-Quarter Results 12Health News:AIDS.gov Goes 2.0: Government HIV/AIDS Website Now Features a Blog, Podcasts, and More 2Health News:Several Therapies Show Promise for Vascular Depression 2Health News:Several Therapies Show Promise for Vascular Depression 3Health News:New target for Alzheimer's disease identified 2Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 2Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 4Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 5Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 6Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 7
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... January 28 ,Amsterdam Molecular Therapeutics (Euronext: AMT), ... therapy, announced today during the Phacilitate Cell ... one treatment of its lead product,Glybera(R) results ... important,lowering of the incidence of acute pancreatitis ...
... Omeros Corporation today announced that it was ... equity and grant funding from The Stanley Medical ... of the Company,s proprietary product candidates for the ... milestone payment to Omeros for having successfully met ...
Cached Medicine Technology:AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly 2AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly 3Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: